← 返回

TOPK 促进肾透明细胞癌中的免疫抑制,并成为一个预后和治疗靶点

英文原题:TOPK promotes immune suppression in kidney renal clear cell carcinoma and emerges as a prognostic and therapeutic target.

查看英文原题

TOPK promotes immune suppression in kidney renal clear cell carcinoma and emerges as a prognostic and therapeutic target.

PubMed 2025/08/18(内容时间) BMC Cancer Q2 · IF 4.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

T-LAK细胞起源的蛋白激酶(TOPK)与多种癌症的不良预后相关,但其在肾透明细胞癌(KIRC)中的具体作用仍不清楚。在本研究中,我们通过整合生物信息学、体外和体内方法,对TOPK在KIRC中的表达及其与免疫浸润的关联进行了全面研究。

我们发现TOPK在KIRC中显著过表达,并作为一种与异常启动子甲基化相关的独立预后标志物。TOPK高表达与细胞毒性免疫细胞浸润减少及免疫检查点表达增加相关,表明其可能在塑造免疫抑制性肿瘤微环境(TME)中发挥作用。功能富集分析进一步将TOPK与关键炎症信号通路联系起来,包括NOTCH1、TNF-α和TGF-β。在免疫健全小鼠中使用TOPK缺陷肿瘤模型进行的体内实验支持其在调节肿瘤相关炎症中的作用。尽管这些实验基于非肾脏肿瘤模型,但研究结果仍为TOPK在体内的免疫调节功能提供了有意义的见解。

总体而言,我们的结果确定TOPK是KIRC中有前景的预后生物标志物和免疫治疗靶点,并为其参与免疫逃逸机制提供了新的视角。

展开英文摘要原文

The T-LAK cell-originated protein kinase (TOPK) has been associated with poor prognosis in various cancers, yet its specific role in kidney renal clear cell carcinoma (KIRC) remains unclear. In this study, we conducted a comprehensive investigation of TOPK expression and its association with immune infiltration in KIRC by integrating bioinformatics, in vitro, and in vivo approaches.

We found that TOPK is significantly overexpressed in KIRC and serves as an independent prognostic marker correlated with aberrant promoter methylation. High TOPK expression was associated with reduced infiltration of cytotoxic immune cells and increased immune checkpoint expression, indicating its potential role in shaping an immunosuppressive tumor microenvironment (TME). Functional enrichment analysis further linked TOPK to key inflammatory signaling pathways, including NOTCH1, TNF-α, and TGF-β.

In vivo experiments using TOPK-deficient tumor models in immunocompetent mice supported its role in modulating tumor-associated inflammation. While these experiments were based on a non-renal tumor model, the findings nonetheless provide meaningful insights into the immunoregulatory function of TOPK in vivo. Collectively, our results identify TOPK as a promising prognostic biomarker and immunotherapeutic target in KIRC, and offer novel perspectives on its involvement in immune evasion mechanisms.

论文信息

作者
Zheng Z、Xiong R、Sui X、Li L、Sun H、Shao C
第一作者单位
Department of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361101, China.China
通讯作者单位
Department of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361101, China. cshao@xah.xmu.edu.cn.China
期刊
BMC cancer2025 Aug 18
原文标识
PubMed 40826334 · DOI 10.1186/s12885-025-14665-0